中牧股份(600195.SH):蘭州布魯氏菌抗體陽性事件預計增加補償費用約3000萬元
格隆匯12月3日丨中牧股份(600195.SH)公佈,2月3日上午,蘭州市政府召開新聞通氣會,介紹蘭州獸研所布魯氏菌抗體陽性事件善後處置工作。截至11月30日,當地累計檢測79357人次,重複檢測10786人次,實際檢測68571人,經甘肅省疾控中心複核確認,抗體陽性人員10528人。
中國農業科學院蘭州獸醫研究所(以下簡稱“蘭州獸研所”)發生布魯氏菌抗體陽性事件後,公司就事件進展情況持續進行了披露。依據蘭州市衞生健康委員會於2020年9月15日晚發佈的《蘭州獸研所布魯氏菌抗體陽性事件處置工作情況通報》,公司已作出相應部署,督促中牧股份蘭州生物藥廠(以下簡稱“蘭州廠”)積極配合省市相關政府部門推進善後處置工作,按照經確認的補償賠償對象,組織實施補償賠償資金支付等工作。
公司於10月31日披露2020年第三季度報告,依據公佈的截至10月10日的人員檢測數據預估可能發生補償金額合計3500萬元,並已作相應計提。按照11月5日蘭州市人民政府、蘭州市衞生健康委員會、農業農村局等多部門,就蘭州市獸研所布魯氏菌抗體陽性事件召開新聞發佈會通報的“省級複核確認陽性人員6620人”計算,預計增加補償費用約1500萬元左右。依據12月3日新聞通氣會公佈的經省疾控中心複核確認的人數計算,在此前補償費用的基礎上預計增加補償費用約3000萬元左右。截至到12月2日,已有3244人簽訂補償賠償協議,涉及金額2417萬元。
由於善後處置工作尚在推進過程中,公司實際發生的處置費用可能與上述預估金額存在差距。本次事件處置對公司2020年經營業績的影響以公司實際發生的處置費用、會計師事務所審計的財務數據為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.